All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …

Pituitary-Tumor Endocrinopathies Pituitary adenomas account for about 15% of intracranial
tumors. Clinical manifestations of disease reflect the oversecretion of the involved hormone …

The classification of neuroendocrine neoplasms (NENs) differs between organ systems and
currently causes considerable confusion. A uniform classification framework for NENs at any …

Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Although usually benign, anterior pituitary tumours occasionally exhibit aggressive
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …

Objective To describe clinical and pathological characteristics and treatment outcomes in a
large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design …

Pituitary neuroendocrine tumors (PitNETs) are common, with five main histological subtypes:
lactotroph, somatotroph, and thyrotroph (POU1F1/PIT1 lineage); corticotroph (TBX19/TPIT …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Hyperprolactinaemia is one of the most common problems in clinical endocrinology. It
relates with various aetiologies (physiological, pharmacological, pathological), the …